NASDAQ:RETA - Reata Pharmaceuticals Stock Price, Forecast & News

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals Inc (NASDAQ:RETA) posted its earnings results on Tuesday, November, 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by $0.07. The company had revenue of $8.24 million for the quarter, compared to analysts' expectations of $7.43 million. Reata Pharmaceuticals had a negative return on equity of 3,281.61% and a negative net margin of 398.84%. The company's revenue was up 59.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.07) EPS. View Reata Pharmaceuticals' Earnings History.

Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Reata Pharmaceuticals.

8 equities research analysts have issued twelve-month target prices for Reata Pharmaceuticals' stock. Their forecasts range from $130.00 to $328.00. On average, they anticipate Reata Pharmaceuticals' share price to reach $255.63 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.

Press coverage about RETA stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Reata Pharmaceuticals.

Some companies that are related to Reata Pharmaceuticals include Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT) and Ono Pharmaceutical (OPHLF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), First Financial Bankshares (FFIN), Precision Drilling (PDS), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Precision Drilling (PD) and Gilead Sciences (GILD).

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Reata Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.12%), Woodstock Corp (0.05%), Penn Davis Mcfarland Inc. (0.02%), Tocqueville Asset Management L.P. (0.01%), Zeke Capital Advisors LLC (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Institutional Ownership Trends for Reata Pharmaceuticals.

RETA stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp, Tocqueville Asset Management L.P. and Nisa Investment Advisors LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.

RETA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Penn Davis Mcfarland Inc. and Zeke Capital Advisors LLC. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass and James W Traweek Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RETA stock can currently be purchased for approximately $211.43.

Reata Pharmaceuticals has a market capitalization of $6.40 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.View Additional Information About Reata Pharmaceuticals.

The official website for Reata Pharmaceuticals is http://www.reatapharma.com/.

Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]